Biomarker Identification for Bladder Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

179 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-21

Study Completion Date

2023-11-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To develop a simple blood and urine test that we would perform before patients start their treatment to predict the risk that their bladder cancer might come back. To develop this test the investigators plan to analyze blood, urine and cancer tissue from bladder cancer patients and follow them closely during and after treatment. This will include looking for changes in proteins and genes that might play a role in bladder cancer biology. The investigators will then compare the information obtained from the studies of blood, urine and cancer tissue between patients that are cured and those whose cancer comes back. The knowledge about these differences between patients can then potentially be used to develop a blood or urine test to tell us who has a high risk for having bladder cancer come back.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors

NCT03662204

Breast Cancer Lung Cancer Colorectal Cancer +10 more

COMPLETED

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

NCT05334069

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Ann Arbor Stage I Lymphoma +59 more

RECRUITING

Cancer DNA Detection in Blood and Urine

NCT02657863

Prostate Cancer

COMPLETED

A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer

NCT00918008

Bladder Cancer

TERMINATED

Urine-DNA Biomarkers in Detecting Bladder Cancer

NCT03066310

Bladder Cancer Biomarker Diagnosis +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bladder Cancer Patients

Patients with muscle invasive bladder cancer. A sample collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.

Sample Collection

Intervention Type PROCEDURE

A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sample Collection

A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients ≥18 years old.
* Patients suspected, clinically diagnosed, or histologically diagnosed bladder cancer.
* Patients undergoing cystoscopy without cancer suspicion.
* Ability to give an informed consent.